Diclofenac gel in the treatment of actinic keratoses

Christopher G Nelson, Christopher G Nelson

Abstract

Actinic keratoses are areas of intraepithelial neoplasia for which treatment is necessary. Because they arise in areas of sun damage, it is desirable to treat the entire damaged field to not only treat visible lesions, but also subclinical, emerging malignancies, ie, "field therapy", 5-fluorouracil, imiquimod, and diclofenac are all treatment options, and are discussed and compared.

Keywords: actinic keratosis; field therapy; review; topical diclofenac.

Figures

Figure 1
Figure 1
Reduction in actinic keratosis (AK) lesions over time. Nelson C, Rigel D; Long term Follow-up of Diclofenac Sodium 3% in 2% Hyaluronic Acid Gel for Actinic Keratoses: One-Year Evaluation. J Clin Aesthet Dermatol. 2009;2(7):20–25. Copyright © 2009 Matrix Medical Communications. All rights reserved. Abbreviations: CLNS, cumulative lesion number score; TLNS, target lesion number score.

References

    1. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):4–7.
    1. Feldman, Fleischer AB, Jr, McConnell C. Most common dermatologic problems identified by internists; 1990–1994. Arch Intern Med. 1998;158(7):726–730.
    1. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994;131(4):455–464.
    1. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):8–10.
    1. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol. 2006;155(1):9–22.
    1. Quatresooz PC, Pierard-Franchimont C, Pauquet P, et al. Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur J Dermatol. 2008;18(1):6–10.
    1. Oppel T, Korting HC. Actinic keratosis: The key event in the evolution from photoaged skin to squamous cell carcinoma. Therapy based on pathogenetic and clinical aspects. Skin Pharmacol Physiol. 2004;17(2):67–76.
    1. Schwartz RA. The actinic keratosis. A perspective and update. Dermatol Surg. 1997;23(11):1009–1019.
    1. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1(8589):795–797.
    1. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42(1 Pt 2):23–24.
    1. Callen JP, Bickers DR, Moy RL. Actinic keratoses. J Am Acad Dermatol. 1997;36(4):650–653.
    1. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol. 2000;42(1 Pt 2):25–28.
    1. Stockfleth E, Ferrandiz C, Grob JJ, et al. Development of a treatment algorithm for actinic keratoses: A European consensus. Eur J Dermatol. 2008;18(6):651–659.
    1. Vatve M, Ortonne JP, Birch-Machin MA, Gupta G. Management of field change in actinic keratosis. Br J Dermatol. 2007;157(Suppl 2):21–24.
    1. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24(6):990–1000.
    1. Jorizzo JL, Carney PS, Ko WT, Robins P, Weinkle SH, Werschler WP. Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: Equivalent efficacy with a lower concentration and more convenient dosing schedule. Cutis. 2004;74(6 Suppl):18–23.
    1. Aldara [Package insert] Bristol, TN: Graceway Pharmaceuticals; 2009.
    1. Quist SR, Gollnick HP. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses. Expert Opin Pharmacother. 2011;12(3):451–461.
    1. Feckler L, Stockfleth E, Braun FK, et al. Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/ hyaluronic acid correlates with downregulation of c-FLIP. J Invest Dermatol. 2010;130(8):2098–2109.
    1. Wolf JE, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40(11):709–713.
    1. Pfleugfelder A, Welter AK, Leiter U, et al. Open label randomized study Comparing 3 months vs 6 months treatment of actinic keratoses with 3% Diclofenac in 2.5% hyaluronic gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol. 2011 Mar 18; doi: 10.1111/j.1468-3083.2011.04005.x.. [Epub ahead of print]
    1. Nelson C, Rigel D. Long-term follow-up of diclofenac sodium 3% in 2.5% hyaluronic acid gel for actinic keratosis: 1-year evaluation. J Clin Aesthet Dermatol. 2009;2(7):20–25.
    1. Nelson CG, Spencer J, Nelson CG., Jr A single-arm, open-label efficacy and tolerability study of diclofenac sodium 3% gel for the treatment of actinic keratosis of the upper and lower lip. J Drugs Dermatol. 2007;6(7):712–717.
    1. Ulrich C, Johannsen A, Röwert-Huber J, Ulrich M, Sterry W, Stockfleth E. Results of a randomized, placebo-controlled safety and efficacy study of topical 3% diclofenac gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol. 2010;20(4):482–488.
    1. Montoro J, Rodriguez M, Diaz M, Bertomeu F. Photoallergic contact dermatitis due to diclofenac. Contact Dermatitis. 2003;48(2):115.
    1. Kerr OA, Kavanagh G, Horn H. Allergic contact dermatitis from topical diclofenac in Solaraze gel. Contact Dermatitis. 2002;47(3):175.
    1. Ueda K, Higashi N, Kume A, Ikushima-Fujimoto M, Ogiwara S. Allergic contact dermatitis due to diclofenac and indomethacin. Contact Dermatitis. 1998;39(6):323.
    1. Patel MJ, Ulrich C, Forschner T. Genetically determined susceptibility to COX-2 inhibitors: A report of exaggerated responders to diclofenac 3% gel in the treatment of actinic keratoses. Br J Dermatol. 2007;156(Suppl 3):57–61.
    1. Romano A, Quaratino D, Papa G, Di Fonso M, Artesani MC, Venuti A. Delayed hypersensitivity to diclofenac: A report on two cases. Ann Allergy Asthma Immunol. 1998;81(4):373–375.
    1. Zimmerman J, Siguencia J, Tsvang E. Upper gastrointestinal hemorrhage associated with cutaneous application of diclofenac gel. Am J Gastroenterol. 1995;90(11):2032–2034.
    1. Jarvis B, Figget DP. Topical 3% diclofenac in 2.5% hyaluronic gel: A review of its use in patients with actinic keratoses. Am J Clin Dermatol. 2003;4(3):203–213.
    1. Ortonne JP, Queille-Roussel C, Duteil L. 3% diclofenac in 2.5% hyaluronic acid (Solaraze) does not induce photosensitivity or phototoxicity alone or in combination with sunscreens. Eur J Dermatol. 2006;16(4):385–390.
    1. Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: Results of a randomized, double blind, vehicle-controlled multicentre, Phase IIa study. Australas J Dermatol. 2009;50(1):16–22.
    1. Ulrich M, Drecoll U, Stockfleth E. Emerging drugs for actinic keratoses. Expert Opin Emerg Drugs. 2010;15(4):545–555.
    1. Spencer J. Multicenter, randomized double blind, vehicle controlled, dose ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.05%, 0.01%, and 0.015% when used to treat actinic keratoses (AK) on the head. Poster 2913, presented at the 60th annual meeting of the American Academy of Dermatology; New Orleans, LA. February 4–8, 2011.
    1. Schmeider G. Multicenter, open-label, dose-area escalation cohort study to evaluate the safety of PEP005 (ingenol mebutate) gel, 0.05% applied for two consecutive days to treatment areas of up to 100 cm2 in patients with actinic keratoses (AK) on the extensor (dorsal aspect) forearms(s). Poster 2915, presented at the 60th annual meeting of the American Academy of Dermatology; New Orleans, LA. February 4–8, 2011.
    1. Swanson N. Multicenter, randomized, parallel-group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.05% in patients with actinic keratoses (AKO on non-head locations. Poster 105, presented at the 60th annual meeting of the American Academy of Dermatology; New Orleans, LA. February 4–8, 2011.
    1. Smith SR, Morhenn VB, Piacquadio GJ. Bilateral comparison of the 3% diclofenac gel and 5% 5-fluorouracil cream in the treatment of actinic keratosis of the face and scalp. J Drugs Dermatol. 2006;5(2):156–159.
    1. Gebauer K, Shumack S, Cowen PS. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for the treatment of actinic keratosis of the forearms and hands: A phase II randomized placebo-controlled trial. Br J Dermatol. 2009;161(4):897–903.
    1. Colombo GL, Chimenti S, Di Matteo S, et al. Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system. G Ital Dermatol Venereol. 2010;145(5):573–581.
    1. Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses. J Drugs Dermatol. 2008;7(7):669–673.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren